Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q86TA1
UPID:
MOB3B_HUMAN
Alternative names:
Mob1 homolog 2b; Mps one binder kinase activator-like 2B
Alternative UPACC:
Q86TA1; Q8NEB4; Q9H8V4
Background:
MOB kinase activator 3B, also known as Mob1 homolog 2b and Mps one binder kinase activator-like 2B, plays a crucial role in the Hippo signaling pathway. This pathway is essential for organ size control and tumor suppression, functioning through the modulation of LATS1 expression to restrict proliferation and promote apoptosis.
Therapeutic significance:
Understanding the role of MOB kinase activator 3B could open doors to potential therapeutic strategies.